Arthur Franken joined Gilde in 2001. He is focusing on venture and growth capital investments in the biopharm, medtech, diagnostics and digital health sectors. He led the investments in Breath Therapeutics (acquired by Zambon), Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche), ProQR Therapeutics (IPO on NASDAQ) and STAT-Dx (acquired by QIAGEN). He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext, acquired by Sanofi-Aventis), Agendia, Axonics (IPO on NASDAQ), Calypso Biotech, uniQure (IPO on NASDAQ), BG Medicine (IPO on NASDAQ), CVRx, FIRE1 and Pieris (IPO on NASDAQ).
He represents Gilde on the boards of Calypso, Levicept and Moximed and served as a board member for Breath Therapeutics, FlowCardia, MTM Laboratories, ProQR Therapeutics and STAT-Dx until the trade sales or IPO.
Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a master’s degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.
+31 30 219 2565